263 related articles for article (PubMed ID: 16078112)
1. HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Raizer JJ
J Neurooncol; 2005 Aug; 74(1):77-86. PubMed ID: 16078112
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy.
Raizer JJ; Abrey LE; Lassman AB; Chang SM; Lamborn KR; Kuhn JG; Yung WK; Gilbert MR; Aldape KA; Wen PY; Fine HA; Mehta M; Deangelis LM; Lieberman F; Cloughesy TF; Robins HI; Dancey J; Prados MD;
Neuro Oncol; 2010 Jan; 12(1):95-103. PubMed ID: 20150372
[TBL] [Abstract][Full Text] [Related]
3. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor.
Nagane M; Narita Y; Mishima K; Levitzki A; Burgess AW; Cavenee WK; Huang HJ
J Neurosurg; 2001 Sep; 95(3):472-9. PubMed ID: 11565870
[TBL] [Abstract][Full Text] [Related]
4. Ribozyme-mediated inhibition of 801-bp deletion-mutant epidermal growth factor receptor mRNA expression in glioblastoma multiforme.
Karpel-Massler G; Wirtz CR; Halatsch ME
Molecules; 2010 Jun; 15(7):4670-8. PubMed ID: 20657384
[TBL] [Abstract][Full Text] [Related]
5. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment.
Berro A; Assi A; Farhat M; Hatoum L; Saad JP; Mohanna R; Bechara AMA; Prince G; Hachem MCR; Zalaquett Z; Kourie HR
Crit Rev Oncol Hematol; 2024 Jun; 198():104365. PubMed ID: 38677355
[TBL] [Abstract][Full Text] [Related]
6. A review on potential heterocycles for the treatment of glioblastoma targeting receptor tyrosine kinases.
Bhusare N; Kumar M
Oncol Res; 2024; 32(5):849-875. PubMed ID: 38686058
[TBL] [Abstract][Full Text] [Related]
7. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.
De Witt Hamer PC
Neuro Oncol; 2010 Mar; 12(3):304-16. PubMed ID: 20167819
[TBL] [Abstract][Full Text] [Related]
8. Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic.
Shabason JE; Tofilon PJ; Camphausen K
J Cell Mol Med; 2011 Dec; 15(12):2735-44. PubMed ID: 21362133
[TBL] [Abstract][Full Text] [Related]
9. EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.
Álvarez-Vázquez A; San-Segundo L; Cerveró-García P; Flores-Hernández R; Ollauri-Ibáñez C; Segura-Collar B; Hubert CG; Morrison G; Pollard SM; Lathia JD; Sánchez-Gómez P; Tabernero A
Neuro Oncol; 2024 Mar; ():. PubMed ID: 38507464
[TBL] [Abstract][Full Text] [Related]
10. The antitumor action of endocannabinoids in the tumor microenvironment of glioblastoma.
Tang Y; Wang M; Yu J; Lv G; Wang Y; Yu B
Front Pharmacol; 2024; 15():1395156. PubMed ID: 38720772
[TBL] [Abstract][Full Text] [Related]
11. The future role of personalized medicine in the treatment of glioblastoma multiforme.
Li J; Di C; Mattox AK; Wu L; Adamson DC
Pharmgenomics Pers Med; 2010; 3():111-27. PubMed ID: 23226047
[TBL] [Abstract][Full Text] [Related]
12. In silico studies on marine actinomycetes as potential inhibitors for Glioblastoma multiforme.
Kirubakaran P; Kothapalli R; Singh KhD; Nagamani S; Arjunan S; Muthusamy K
Bioinformation; 2011 Apr; 6(3):100-6. PubMed ID: 21584184
[TBL] [Abstract][Full Text] [Related]
13. CR13626: a novel oral brain penetrant tyrosine kinase inhibitor that reduces tumor growth and prolongs survival in a mouse model of glioblastoma.
Galimberti C; Piepoli T; Letari O; Artusi R; Persiani S; Caselli G; Rovati LC
Am J Cancer Res; 2021; 11(7):3558-3574. PubMed ID: 34354860
[TBL] [Abstract][Full Text] [Related]
14. Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?
Veliz I; Loo Y; Castillo O; Karachaliou N; Nigro O; Rosell R
Ann Transl Med; 2015 Jan; 3(1):7. PubMed ID: 25705639
[TBL] [Abstract][Full Text] [Related]
15. HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy.
Lee JY; Park J; Hong D
Anim Cells Syst (Seoul); 2024; 28(1):216-227. PubMed ID: 38770056
[TBL] [Abstract][Full Text] [Related]
16. Recurrent Glioblastoma: Where we stand.
Roy S; Lahiri D; Maji T; Biswas J
South Asian J Cancer; 2015; 4(4):163-73. PubMed ID: 26981507
[TBL] [Abstract][Full Text] [Related]
17. Development of targeted therapies in treatment of glioblastoma.
Xu YY; Gao P; Sun Y; Duan YR
Cancer Biol Med; 2015 Sep; 12(3):223-37. PubMed ID: 26487967
[TBL] [Abstract][Full Text] [Related]
18. Reuse of Molecules for Glioblastoma Therapy.
Koehler A; Karve A; Desai P; Arbiser J; Plas DR; Qi X; Read RD; Sasaki AT; Gawali VS; Toukam DK; Bhattacharya D; Kallay L; Pomeranz Krummel DA; Sengupta S
Pharmaceuticals (Basel); 2021 Jan; 14(2):. PubMed ID: 33525329
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E; Mercier MC; Etienne-Selloum N; Dontenwill M; Choulier L
Cancers (Basel); 2021 Apr; 13(8):. PubMed ID: 33918704
[TBL] [Abstract][Full Text] [Related]
20. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment.
Hanif F; Muzaffar K; Perveen K; Malhi SM; Simjee ShU
Asian Pac J Cancer Prev; 2017 Jan; 18(1):3-9. PubMed ID: 28239999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
